Quantcast
Last updated on April 17, 2014 at 7:54 EDT

Latest Amines Stories

2014-01-14 04:21:01

SEATTLE, Jan. 14, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced a corporate update for 2014 in addition to an overview of recent progress for its drug portfolio. "We ended 2013 and have entered 2014 with a series of successes, including a global strategic partnership for pacritinib, positive reimbursement rulings in England/Wales and Germany for PIXUVRI, the reacquisition of rights to PIXUVRI and Opaxio in order to allow us to more efficiently move...

2014-01-13 12:28:09

To combat the advance of painkiller abuse around the world, the leading supplement for withdrawal is going global AUSTIN, Texas, Jan. 13, 2014 /PRNewswire/ -- In an effort to combat global prescription drug abuse, Withdrawal Ease -- the leading nutritional supplement system designed to help ease the physical and emotional discomfort of withdrawal -- has announced its launch into Canada and Australia. Countries in the U.K., Europe and South America are expected to follow later in...

2014-01-09 12:26:30

CORALVILLE, Iowa, Jan. 9, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that president and CEO, Travis Mickle, Ph.D. will present at the Biotech Showcase(TM) 2014 Conference being held in San Francisco January 13-15, 2014. Among the topics to be discussed, Dr. Mickle will provide an overview of KemPharm's development pipeline, including KP201, the...

2014-01-02 08:23:03

FYCOMPA is the First and Only FDA-Approved Non-Competitive AMPA Glutamate Receptor Antagonist WOODCLIFF LAKE, N.J., Jan. 2, 2014 /PRNewswire/ -- Eisai Inc. announced today that FYCOMPA(TM) (perampanel) CIII will be available to eligible patients by prescription in the U.S. beginning January 6, 2014. FYCOMPA is an adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy age 12 years and older. FYCOMPA is...

FDA Warning Issued On ADHD Drug Due To Painful Priapism
2013-12-17 15:58:44

Brett Smith for redOrbit.com - Your Universe Online A type of stimulant used to treat attention deficit disorders can lead to the development of long-lasting and sometimes painful erections, the Food and Drug Administration (FDA) said in a written warning released on Tuesday. The condition, referred to as priapism, was linked in an FDA review to males between 8 to 33 years of age who took drugs containing methylphenidate, the active ingredient in Ritalin and Concerta. “Patients who...

2013-12-12 23:03:30

Authors of an article featured in the current issue of Weed Technology collected waterhemp seed samples across Missouri to identify factors leading to glyphosate resistance. Over two-thirds of the weed sampled from soybean fields were shown to be resistant to the herbicide. Lawrence, KS (PRWEB) December 12, 2013 Weed Technology –Waterhemp is one of the most common weed species found in Midwest field crops. A member of the pigweed (Amaranth) family, this summer annual is capable of...

2013-12-12 12:27:32

MUMBAI, India and BALTIMORE, December 12, 2013 /PRNewswire/ -- Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has launched its Duloxetine Hydrochloride Delayed-release (HCl DR) Capsules 20 mg, 30 mg and 60 mg strengths. The Company received final approval to market its Duloxetine HCl DR Capsules USP, 20 mg, 30 mg, 40 mg and 60 mg strengths from the United States Food and Drugs Administration (FDA) yesterday....

2013-12-09 12:25:58

Approximately Three-Quarters of Gilotrif Nonprescribers Anticipate Prescribing Gilotrif Within the Next Six Months, According to a New Report from BioTrends Research Group EXTON, Pa., Dec. 9, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, one month post-launch in the United States, more than a quarter of surveyed U.S. medical oncologists have prescribed Boehringer Ingelheim's...

2013-12-06 23:21:10

In response to the prescription pain killer and opiate addiction epidemic, VitaPro Labs launches their all-natural herbal remedy to ease opioid withdrawal symptoms. This innovative system is designed to minimize the symptoms of withdrawal and speed up the detox process. New York City, NY (PRWEB) December 06, 2013 Withdrawal Aid was developed by an addictive medicine doctor and is proven to help cure symptoms that originate from opiate withdrawal. The system available at WithdrawalAid.com...

2013-12-05 08:29:48

WOODCLIFF LAKE, N.J., Dec. 5, 2013 /PRNewswire/ -- Today, Eisai Inc. announced that 16 abstracts highlighting new data analyses on FYCOMPA (perampanel) will be presented at the 67(th) annual American Epilepsy Society (AES) meeting, taking place in Washington, D.C. from December 6 - 10. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO) "These data analyses highlight Eisai's clinical research with FYCOMPA, reinforcing our commitment to the epilepsy community," said Lynn Kramer,...